The phase III open-label study (IMbrave 150) in advanced HCC patients treated with combination atezo+bev, a humanized anti-VEGF monoclonal antibody, demonstrated that the hazard ratio for death with atezo+bev as compared with sorafenib was 0.58 in the primary analysis. The gene discussed is VEGFA; the disease is hepatocellular carcinoma.